BGY vs BME
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard shows a strong Piotroski F-Score of 7/9, indicating solid financial health, but the absence of an Altman Z-Score limits distress risk assessment. Despite high profitability margins and strong historical price performance, the stock trades at a steep valuation (P/E 45.92 vs. sector avg 31.01) with declining revenue and an unsustainable dividend payout ratio of 366.15%. Technical trend is deeply bearish (10/100), and lack of analyst coverage further increases uncertainty. These factors outweigh the strong F-Score and high yield, leading to a bearish outlook.
The Advanced Deterministic Scorecard reveals a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full bankruptcy risk assessment. Despite a high dividend yield of 7.43%, the unsustainable 162.83% payout ratio raises concerns about dividend continuity. Profitability metrics show mixed signals with a 100% gross margin but zero profit margin and negative ROE of -4.63%, suggesting underlying operational inefficiencies. The technical trend score of 10/100 indicates strong bearish momentum, further weakening the investment case.
Compare Another Pair
Related Comparisons
BGY vs BME: Head-to-Head Comparison
This page compares BlackRock Enhanced International Dividend Trust (BGY) and BlackRock Health Sciences Trust (BME) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.